ROSALIND ADVISORS INC
Q1 2025 Form 13-F
TORONTO, ONTARIO, CANADA
CIK 0001622627
· Institutional investment manager
$205.6M Reported Value Total
Reported value
$205.6M
Quarter over quarter
+1.2%
Holdings
31
Top-10 concentration
63.4%
Key People
Named on the latest Form 13-F filing — not necessarily an owner
Steven Salamon
President, Rosalind Advisors, Inc.
Filing Navigation
13F Metrics
Loading 13F Metrics
Q1 2025 13F record
Q1 2025 13F filing summary
| Period of report | March 31, 2025 |
|---|---|
| Filed | May 14, 2025 |
| Form | 13F-HR |
| Reported value | $205.6M |
| Positions | 31 |
| Change in reported value | +5.2% |
| New positions | 7 |
| Exited positions | 4 |
| Position turnover | 31.4% |
| Top-10 concentration | 63.4% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 16, 2026
|
35 | $311.9M |
|
Q2 2026 13F
Filed Aug 14, 2026
|
29 | $269.2M |
|
Q1 2026 13F
Filed May 14, 2026
|
32 | $248.9M |
|
Q4 2025 13F
Filed Feb 12, 2026
|
29 | $284.5M |
|
Q3 2025 13F
Filed Nov 13, 2025
|
29 | $292.6M |
|
Q2 2025 13F
Filed Aug 14, 2025
|
29 | $210.9M |
|
Q1 2025 13F
Filed May 14, 2025
|
31 | $205.6M |
|
Q4 2024 13F
Filed Feb 11, 2025
|
28 | $195.6M |
|
Q3 2024 13F
Filed Oct 30, 2024
|
29 | $156.2M |
|
Q2 2024 13F
Filed Jul 12, 2024
|
35 | $130.0M |
|
Q1 2024 13F
Filed Apr 25, 2024
|
31 | $107.0M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
27 | $121.4M |
Top 20 holdings · Q1 2025
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | DCTH DELCATH SYS INC | $29.0M | 14.1% |
| 2 | VSTM VERASTEM INC | $15.9M | 7.75% |
| 3 | XERS XERIS BIOPHARMA HOLDINGS INC | $13.7M | 6.66% |
| 4 | MYO MYOMO INC | $13.0M | 6.32% |
| 5 | IDYA IDEAYA BIOSCIENCES INC | $11.5M | 5.58% |
| 6 | FENC FENNEC PHARMACEUTICALS INC | $10.9M | 5.28% |
| 7 | URGN UROGEN PHARMA LTD | $10.5M | 5.11% |
| 8 | OCUL OCULAR THERAPEUTIX INC | $8.9M | 4.34% |
| 9 | ABEO ABEONA THERAPEUTICS INC | $8.6M | 4.18% |
| 10 | REPL REPLIMUNE GROUP INC | $8.3M | 4.03% |
| 11 | VRDN VIRIDIAN THERAPEUTICS INC | $8.0M | 3.9% |
| 12 | MDWD MEDIWOUND LTD | $7.9M | 3.83% |
| 13 | SVRA SAVARA INC | $7.4M | 3.58% |
| 14 | VRNA VERONA PHARMA PLC | $6.3M | 3.09% |
| 15 | NSPR INSPIREMD INC | $6.1M | 2.98% |
| 16 | CYBN CYBIN INC | $5.1M | 2.5% |
| 17 | NUVB NUVATION BIO INC | $4.3M | 2.1% |
| 18 | PROF PROFOUND MED CORP | $4.0M | 1.96% |
| 19 | TRVI TREVI THERAPEUTICS INC | $3.9M | 1.87% |
| 20 | PHVS PHARVARIS N V | $3.5M | 1.71% |
Values as reported on the Q1 2025 Form 13F. Every position is in the holdings table below.